The influence of age on the outcome of follicular non-Hodgkin's lymphoma (FL) was studied in a population-based non-Hodgkin's lymphoma registry.
Introduction
Over the past 30 years, the treatment of follicular nonHodgkin's lymphoma (FL) has not resulted in a major breakthrough. Whereas FL patients as a whole experience a median survival of ∼7-10 years, several subgroups can be discerned, each predicting a better or worse survival. Among these, the age of the patient and pathology grading of the FL are probably the most important predictive factors. With regard to the latter, the recognition of three histological grades, based upon the number of centroblasts, is common practice, although there is no consensus on the method of grading. As a compromise, the World Health Organization (WHO) Classification suggested the use of at least two grades by proposing the grouping of grades 1 and 2 [1, 2] . In this classification, grade 1 and 2 FL behave similarly in natural history and treatment response, thereby differing from grade 3. However, the NonHodgkin's Lymphoma Classification Project (NHLCP) did not distinguish between the three grades in its reports on treatment results of the non-Hodgkin's lymphomas [3] [4] [5] , as was done in the development of a prognostic model for this lymphoma [6, 7] . Others reported separately on grade 1 and 2 FL with respect to prognostic factors and treatment results [8, 9] , and noticed the similarity between grade 3 FL and diffuse large B-cell lymphoma with regard to outcome [10] [11] [12] .
Age-related differences in the outcome of non-Hodgkin's lymphomas (NHL) are well known [4, 13] . In a previous analysis on patients in a population-based NHL registry the denominator elderly was given to patients >70 and >65 years of age, for indolent and aggressive NHL, respectively [14] . To determine more precisely the fate of patients with FL, and the impact of grade in an unselected group of patients, we analyzed the data with respect to the age groups <60, 60-69 and ≥70 years from the Comprehensive Cancer Center West (CCCW) NHL registry. In addition, we paid special attention to the relative and cause-specific survival (CSS) and to the prognostic scoring systems according to the International Prognostic Index (IPI) [15] and Italian Lymphoma Intergroup (ILI) [7] .
Patients and methods
A thorough analysis according to age in this population-based NHL registry has been reported previously [13, 14] . In summary, all new cases with NHL in the region covered by the CCCW (The Netherlands; covering 1.6 million inhabitants) were prospectively registered from June 1981 to December 1989. After exclusion of patients with primary cutaneous T-cell lymphoma, classical chronic lymphocytic leukemia, acute lymphoblastic leukemia, multiple myeloma, plasmocytoma or a post-mortem diagnosis only of NHL, this amounted to 1168 patients. The histological diagnosis had to be confirmed by a panel of hematopathologists. The subclassification of FL was performed, in accordance with the NHL Pathologic Classification Project [16] , into the following categories: predominantly small, mixed small and large, and predominantly large cell. According to this system, in the CCCW registry the cut-off points were <20%, 20-50% and >50% centroblasts, respectively. The REAL classification recommended the terminology grade 1, grade 2 and grade 3, but did not recommend any specific criteria [17] . However, the WHO recommendation for the grading of FL is based on the exact counting of the number of centroblasts in 10 neoplasic follicles, expressed per 40× high-power microscopic field [2] . Because this was not performed in the CCCW registry and to avoid any confusion we decided to use the terminology grade I/II FL and grade III FL for FL with <50% and >50% centroblasts, respectively.
Staging was based on the Ann Arbor system [18] . Among grade I/II patients the three age groups showed adequate staging for 86, 87 and 65% of patients, respectively. Among grade III patients this was true for 89, 80 and 36% of patients, respectively. Inadequate staging was due mainly to the omission of a bone marrow biopsy.
Although consensus on treatment was reached within the NHL Study Group of CCCW, the choice of treatment was the responsibility of the local physician. Until 1989, the general guidelines for FL were radiotherapy for localized lymphomas, cyclophosphamide, vincristine, prednisone (CVP) chemotherapy or chlorambucil for stage III-IV grade I/II FL, cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) chemotherapy for stage II-IV grade III FL, followed by radiotherapy for bulky tumors or persistent lesions.
Treatment outcome was related to complete remission rate, overall survival (OS), relative survival and CSS. Overall survival was calculated from diagnosis until death (all causes, event) or last follow-up (censored; July 2000). The OS per age group was compared to the expected survival for a cohort of the general Dutch population (data obtained from Statistics Netherlands) with the same age and sex distribution. Relative survival probabilities, defined as observed survival probability divided by the expected survival probability, were calculated using Hakulinen's relative survival software [19] . The causes of death were divided among NHL, toxicity of treatment, other malignancies, concomitant diseases and unknown. Cause-specific survival was determined for the four known categories and was censored by death not due to NHL or treatment-related toxicity.
As prognostic factors for survival, we considered, along with age, the number of extranodal sites, serum lactate dehydrogenase (LDH), performance status (Karnofsky index) and stage to determine the IPI [15] , as well as gender and erythrocyte sedimentation rate (ESR). Because an ageadjusted ILI has not been validated, we omitted an age-adjusted analysis of the IPI. The prognostic model according to ILI identified age, gender, number of extranodal sites, B-symptoms, serum LDH and ESR as predictive factors for OS [7] . However, no cases presented with all six adverse factors and therefore three risk groups determined by five adverse factors were considered. Although information about B-symptoms was lacking in the CCCW database, the application of the ILI model, using the remaining five variables, was considered appropriate. Like ILI we defined three risk groups in both scoring systems: low (score 0-1), intermediate (score 2) and high (score 3-5) [7] .
Statistical analyses were performed using chi-square tests for trends to compare percentages in cross tabulations, and the log-rank test to compare Kaplan-Meier survival curves. The prognostic factors were analyzed by Cox proportional hazards regression model.
Results
The clinical characteristics of 214 patients with FL according to the age groups <60, 60-69 and ≥70 years are given in Table 1 for patients with grade I/II FL (n = 171) and in Table 2 for patients with grade III FL (n = 43). Testing for trend between the three age groups in patients with grade I/II FL only showed a statistically significant difference for elevated ESR (P = 0.001), showing more often elevated values in the older age groups. With respect to the prognostic scoring systems, both IPI and ILI showed a delineation between the age groups: a low score (0-1) especially among patients <60 years of age, while a high score (3-5) was most frequently seen among patients >70 years of age. Forty-four percent of all grade I/II FL patients were in the IPI low risk group, 32% in the intermediate risk group and 24% in the high risk group, while for ILI the distribution was 52, 29 and 19%, respectively.
Among patients with grade III FL, most patients <60 years of age were in the low risk group, both in the IPI and ILI risk models. Fifty-three percent of all grade III FL patients were in the IPI low risk group, 35% in the intermediate risk group and 12% in the high risk group, while for ILI, the distribution was 49, 32 and 19%, respectively. In the younger age group (<60 years of age) LDH showed significantly more often elevated values in comparison with FL grade I/II patients (P = 0.04). In addition, significantly fewer patients (0-7%) had extranodal localizations compared with the FL I/II group (P = 0.01; Tables 1 and 2 ). Finally, initial therapy with anthracyclins was given significantly less often to FL grade III patients as age increased (P = 0.006). Table 3 shows outcome of treatment among the three age groups. For the whole cohort of 214 patients the median follow-up was 110 months (range 11-183). The complete remission rate decreased among patients >70 years of age, and this was statistically significant for grade I/II FL (P = 0.03 versus 0.43 for grade III FL). The difference in OS between the age groups was statistically significant among grade I/II patients (P <0.001 versus P = 0.22 for grade III FL). However, by Cox-regression analysis the hazard ratio for death increased in the older age groups, in both grade I/II or grade III FL patients. Among grade I/II patients, the hazard ratio was 1.9 [95% confidence interval (CI) 1.2-2.9] and 2.7 (95% CI 1.8-4.0), respectively, for age groups 60-69 and >70 years. Among grade III patients, this was 1.3 (95% CI 0.5-3.1) and 1.9 (95% CI 0.9-4.1), respectively. Overall survival curves per age group, together with the curves for CSS and survival of the Dutch population at large, are shown in Figure 1A -F. The relative survival curves, showing the same trends as the CSS curves, have been omitted for the sake of clarity. For the whole cohort, the difference in OS between grade I/II versus grade III patients was statistically significant (log-rank test P = 0.03). Considering CSS, the cause of death was known for 89% of patients. NHL and toxicity of treatment contributed to the cause of death in 80, 66 and 52% of patients with grade I/II FL in the three respective age groups. Among patients with grade III FL, the rates were 100, 88 and 58%, respectively. Considering grade I/II FL, the CSS was not much different from OS for patients <60 years of age only ( Figure 1A ). With respect to grade III FL, this held true for the two age groups <60 and 60-69 years of age ( Figure 1D-E) . In other words: the chance of death from an unrelated disease increases for patients >60 years of age with grade I/II FL and for patients >70 years of age with grade III FL.
The prognostic values of the variables LDH, Karnofsky index, stage, gender, more than one extranodal site, ESR and age, determined by a Cox regression analysis, are shown in Table 4 . For patients with grade I/II FL, especially serum LDH, Karnofsky score and an age ≥70 years appeared to be important for prognosis. For patients with grade III FL this held true for serum LDH and stage. Testing for interaction between follicular grade and the other risk factors in the multiple Cox regression model showed that the hazard ratios between grade I/II and grade III FL differed significantly for serum LDH (P = 0.02) and stage III-IV (P = 0.001).
The OS curves according to IPI and ILI for the low (0-1), intermediate (2) and high (3-5) risk scores are shown in Figure 2A -D separately for grade I/II and grade III FL. The ILI risk score discriminated best for grade I/II (log-rank test for trend by ILI 34.1, df = 1, P <0.001; log-rank test for trend by IPI 22.07, df = 1, P <0.001), while the IPI risk score discriminated best for grade III (log-rank test by ILI 4.93, df = 1, P = 0.03; log-rank test by IPI 10.7, df = 1, P = 0.001). Table 5 shows the 5-and 10-year survival rates according to both risk models and separately for grade I/II and grade III FL.
Discussion
This study stresses the differences between grade I/II versus grade III FL and stipulates the importance of considering agerelated differences in outcome. (12) 30 (14) 27 (11) 10-year, % (SE) 19 (10) 30 (14) 20 (10) Median survival (months) (SE) 45 (17) 18 (13) 11 (3) Figure 1 . (A-F) Overall survival and cause-specific survival in relation to the survival of the Dutch population at large for the three age groups, separately for grade I/II and grade III follicular non-Hodgkin's lymphoma. The data for the expected survival of the Dutch population were obtained from Statistics Netherlands. Cause-specific survival was censored by death not due to non-Hodgkin's lymphoma or treatment-related toxicity.
A comparison with respect to characteristics and treatment results of follicular lymphoma, reported in different series, is given in Table 6 . There is little consistency in the proportion of the characteristics among patients in the different series, which it is assumed is related to the inclusion criteria used for the different treatment protocols. What was especially apparent was the decrease in performance among grade I/II patients in the current series compared with other grade I/II series [8, 9] . Furthermore, the distribution of age groups (more elderly patients) is different between population-based series (current CCCW and Nebraska Lymphoma Study Group [20] ) as opposed to institutional or referral-based series. The finding that both IPI and ILI showed the low risk category to be patients <60 years of age and the high risk category those patients >70 years of age can be explained, in part, by the fact that both scoring systems consider age >60 years as a risk factor. In our series the probability of increased LDH among grade I/II patients was especially apparent for patients >60 years of age. With respect to elevated ESR, the CCCW registry showed a statistically significant difference among the three age groups of grade I/II patients. According to ILI an elevated ESR (besides the presence of B-symptoms) forms an important prognostic factor [7] , thus probably attributing (as well as increased LDH) to the inferior prognosis among elderly patients in our series.
When considering the initial treatment, it appeared that 40% of the patients in the CCCW registry with grade III FL received anthracycline-based chemotherapy, but this dropped to 13% among patients >70 years of age. In this way the difference between a population-based strategy and treatment decisions for patients in other series (institution protocols [10, 12, 20] and trial protocols [11] ), where most patients were treated with anthracycline-based chemotherapy, is remarkable.
Different complete response (CR) rates are reported in the literature depending on the techniques and diligence used to assess residual disease [21] . The CR rate per age group in our series was roughly the same, irrespective of grade. The chance to obtain complete remission was lower among patients >70 years of age (as was shown by the NHLCP [4] ), and this was statistically significant for patients with grade I/II FL. However, the value of establishing complete remission in FL I/II patients, for whom deferred treatment in cases of low tumor burden does not jeopardize the survival rate [21, 22] , can be argued.
The OS rate was inferior among the older age groups, which is especially apparent from the Cox-regression analysis. The hazard ratios for age were not significantly different between grade I/II and grade III FL (P = 0.97). Among grade I/II patients, the age group <60 years showed a median survival of 103 months, which conforms to the Stanford series [21] . For the age groups 60-69 and ≥70 years this dropped to 73 and 46 months, respectively. In their report on age-related differences in the behavior of NHL, the NHLCP showed decreased survival rate in patients >70 years of age (and <35 years of age!) with FL in all grades (29% of that cohort had grade III FL) [4] . The Nebraska group found significantly decreased survival among patients >60 years of age and with stage I/II FL (75% of these patients had grade III FL) [23] . More series confirmed age >60 years as an adverse prognostic factor [6, 9] .
With respect to grade III FL, the median survival in our series appeared to be 45, 18 and 11 months for the three respective age groups. The Nebraska group found significantly decreased survival for patients >70 years of age and with stage III/IV disease only [20] . The Group d'Etude des Lymphomes d'Adulte (GELA) group, in their analysis of patients with grade III FL, found that age >60 years was a statistically significant adverse prognostic factor [11] , but other series did not confirm this age cut-off [10, 24] . A plateau forming in the OS curves was especially apparent for grade III FL, foremost in the age group <60 years. Most series with 
5-year, % (SE) 84 (5) 77 (5) 56 (12) 44 (12) 10-year, % (SE) 49 (7) 40 (6) 30 (12) 26 (11) Intermediate (2) n = 45 n = 44 n = 12 n = 12 5-year, % (SE) 49 (7) 57 (7) 17 (11) 33 (14) 10-year, % (SE) 8 (5) 23 (7) 17 (11) 25 (13) High ( [24] . In that series an age-dependent analysis of CSS was not performed. Also in the Nebraska series the difference in survival between patients <60 and >60 years of age with stage I/II FL (75% grade III) was no longer evident when looking at CSS data [23] ; this has also been demonstrated for other types of aggressive NHL [26] . However, for grade I/II FL patients a CSS analysis was not different from OS in another MD Anderson series [8] . In that series age (>60 versus <60 years of age) was not significantly correlated with CSS.
The prognostic scoring system of the IPI seems less optimal for follicular lymphoma [27] , because of the low number of patients in the higher risks groups [10, 12, 24] . The large series of ILI identified age, gender, B-symptoms, number of extranodal sites, serum LDH and elevated ESR as key features for prognosis of FL (irrespective of grade) [7] . In our populationbased series, which lacked information on B-symptoms, we identified elevated LDH, Karnofsky performance status ≤70 and age >70 years as the main prognostic factors for grade I/II FL patients, whereas elevated LDH and stage III/IV disease were the main prognostic determinants among grade III FL patients. Of course, the low number of patients (especially with respect to grade III FL) contributes to the fact that statistical significance was not reached for the other prognostic factors. By comparing the OS curves according to IPI and ILI, we were able to confirm that the ILI scoring system resulted in a better prognostic differentiation for patients with grade I/II FL than the IPI system. The latter was better at discriminating between patients with grade III FL, thus supporting the concept that grade III FL should be treated as a separate entity to grades I and II, with its properties of aggressive NHLs.
Several conclusions can be drawn from the analysis of this population-based cohort of patients with follicular nonHodgkin's lymphoma. First, the achievement of complete remission was not different for grade I/II versus grade III, both showing decreased CR rate >70 years of age. Secondly, older age groups showed a decrease in the OS, whether grade I/II or grade III (Cox model). Thirdly, the median survival was lower for patients with grade III FL, irrespective of age group. However, the plateau observed in the survival curve, shown foremost by the CSS analysis, confirms the separate status of grade III FL being more akin to diffuse large B-cell lymphoma. Fourthly, the prognostic scoring system according to ILI fitted better to grade I/II FL patients, while the IPI system appeared more appropriate among grade III FL patients.
The patients in this population-based cohort have been treated according to classical guidelines of the 1980s. The new treatment options of the 1990s will hopefully lead to a longsought after survival advantage for FL [27] . A thorough understanding of pre-existing risk factors and age-related differences should be helpful in the design of new studies and the interpretation of treatment data.
